Long noncoding RNAs: new insights into non-small cell lung cancer biology, diagnosis and therapy

被引:0
作者
Biagio Ricciuti
Clelia Mencaroni
Luca Paglialunga
Francesco Paciullo
Lucio Crinò
Rita Chiari
Giulio Metro
机构
[1] Azienda Ospedaliera di Perugia,Medical Oncology, Santa Maria della Misericordia Hospital
[2] Azienda Ospedaliera di Perugia,Internal Medicine, Santa Maria della Misericordia Hospital
来源
Medical Oncology | 2016年 / 33卷
关键词
NSCLC; Protein-coding genes; Long noncoding RNAs; Cancer epigenetics; Biomarkers;
D O I
暂无
中图分类号
学科分类号
摘要
Recent advances in tiling array and high throughput analyses revealed that at least 87.3 % of the human genome is actively transcribed, though <3 % of the human genome encodes proteins. This unexpected truth suggests that most of the transcriptome is constituted by noncoding RNA. Among them, high-resolution microarray and massively parallel sequencing analyses identified long noncoding RNAs (lncRNAs) as nonprotein-coding transcripts. lncRNAs are largely polyadenylated and >200 nucleotides in length transcripts, involved in gene expression through epigenetic and transcriptional regulation, splicing, imprinting and subcellular transport. Although lncRNAs functions are largely uncharacterized, accumulating data indicate that they are involved in fundamental biological functions. Conversely, their dysregulation has increasingly been recognized to contribute to the development and progression of several human malignancies, especially lung cancer, which represents the leading cause of cancer-related deaths worldwide. We conducted a comprehensive review of the published literature focusing on lncRNAs function and disruption in nonsmall cell lung cancer biology, also highlighting their value as biomarkers and potential therapeutic targets. lncRNAs are involved in NSCLC pathogenesis, modulating fundamental cellular processes such as proliferation, cell growth, apoptosis, migration, stem cell maintenance and epithelial to mesenchymal transition, also serving as signaling transducers, molecular decoys and scaffolds. Also, lncRNAs represent very promising biomarkers in early-stage NSCLC patients and may become particularly useful in noninvasive screening protocols. lncRNAs may be used as predictive biomarkers for chemotherapy and targeted therapies sensitivity. Furthermore, selectively targeting oncogenic lncRNAs could provide a new therapeutic tool in treating NSCLC patients. lncRNAs disruption plays a pivotal role in NSCLC development and progression. These molecules also serve as diagnostic, prognostic and predictive biomarkers. Characterization of lncRNA genes and their mechanisms of action will enable us to develop a more comprehensive clinical approach, with the final goal to benefit our patients.
引用
收藏
相关论文
共 229 条
[1]  
Siegel R(2014)Cancer statistics, 2014 CA Cancer J Clin 64 9-29
[2]  
Ma J(2014)The 2015 WHO classification of lung tumors Pathologe 35 188-181
[3]  
Zou Z(2007)Epidermal growth factor receptor mutations in lung cancer Nat Rev Cancer 7 169-4253
[4]  
Travis WD(2009)Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK J Clin Oncol 27 4247-870
[5]  
Sharma SV(2012)ROS1 rearrangements define a unique molecular class of lung cancers J Clin Oncol 30 863-705
[6]  
Bell DW(2014)Non-coding RNAs in lung cancer Oncoscience 1 674-108
[7]  
Settleman J(2012)Landscape of transcription in human cells Nature 489 101-42
[8]  
Shaw AT(2007)Eukaryotic regulatory RNAs: an answer to the ‘genome complexity’ conundrum Genes Dev 21 11-1789
[9]  
Yeap BY(2012)The GENCODE v7 catalog of human long noncoding RNAs: analysis of their gene structure, evolution, and expression Genome Res 22 1775-419
[10]  
Mino-Kenudson M(2012)Mechanistic roles of noncoding RNAs in lung cancer biology and their clinical implications Genet Res Int 2012 737416-779